How Often Should You Repeat Stem Cell Treatments?

Why "one and done" is oversold

Regenerative medicine marketing often frames a single treatment as a durable fix. In practice, published follow-up data show a spectrum — some patients maintain benefit at 12 or 24 months from a single injection, others report gradual regression toward baseline in the second half of the first year. Which pattern you fall into depends on the condition, its severity, the dose delivered, and post-treatment behavior. Anyone quoting a fixed "years of relief" figure at intake is guessing.

Retreatment intervals by condition type

Orthopedic (osteoarthritis, tendinopathy)

Published protocols vary widely. Common patterns:

• Knee or hip osteoarthritis: reassess symptoms at 6–9 months; consider retreatment at 12–18 months if benefit is regressing.
• Tendon indications (Achilles, elbow, rotator cuff): retreatment at 3–6 months if initial response was partial; longer intervals if response was durable.
• Combination protocols (cells + PRP): PRP "boosters" every 3–6 months are common between primary cell treatments.

Systemic conditions (autoimmune, degenerative)

Published trials often use series protocols — 2–3 IV infusions over weeks — rather than one-and-done. Retreatment cycles at 6–12 months are typical when benefit is being maintained. This is closer to a chronic-disease management model than an acute fix.

Neurological conditions

Where treated at all, protocols usually involve series infusions with reassessment intervals of 3–6 months. Given how modest expected effects are, retreatment decisions should be data-driven — objective measurement of function before and after, not just felt sense.

What clinics with skin in the outcome look like

Serious programs measure outcomes at defined intervals (baseline, 6 weeks, 3 months, 6 months, 12 months) using validated instruments (WOMAC, VAS, KOOS, Oswestry, condition-appropriate measures) and use those numbers to guide retreatment decisions. Programs that offer packages of "3 treatments over 12 months" regardless of individual response are selling a schedule, not medicine.

Questions worth asking

• What outcome measures will you track, and at what intervals?
• At what threshold of improvement or regression would you recommend retreatment vs a different approach?
• What is your rate of patients who return for retreatment within 12 months, and what does that tell you about your protocol?
• Do you offer refunds or discounts if the first treatment does not produce measurable improvement?